Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Depreciation and Depletion (2024 - 2025)

United Therapeutics' Depreciation and Depletion history spans 2 years, with the latest figure at $22.7 million for Q4 2025.

  • For Q4 2025, Depreciation and Depletion rose 17.01% year-over-year to $22.7 million; the TTM value through Dec 2025 reached $84.7 million, up 18.3%, while the annual FY2025 figure was $84.7 million, 18.3% up from the prior year.
  • Depreciation and Depletion for Q4 2025 was $22.7 million at United Therapeutics, up from $21.5 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $22.7 million in Q4 2025 and bottomed at $14.8 million in Q1 2024.